These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 34035459)

  • 1. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
    Zorko NA; Ryan CJ
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):986-996. PubMed ID: 34035459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell-engaging therapies - BiTEs and beyond.
    Goebeler ME; Bargou RC
    Nat Rev Clin Oncol; 2020 Jul; 17(7):418-434. PubMed ID: 32242094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
    Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
    Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies.
    Porter LH; Harrison SG; Risbridger GP; Lister N; Taylor RA
    J Steroid Biochem Mol Biol; 2024 Oct; 243():106571. PubMed ID: 38909866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TriKEs and BiKEs join CARs on the cancer immunotherapy highway.
    Tay SS; Carol H; Biro M
    Hum Vaccin Immunother; 2016 Nov; 12(11):2790-2796. PubMed ID: 27322989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanobodies in cell-mediated immunotherapy: On the road to fight cancer.
    Maali A; Gholizadeh M; Feghhi-Najafabadi S; Noei A; Seyed-Motahari SS; Mansoori S; Sharifzadeh Z
    Front Immunol; 2023; 14():1012841. PubMed ID: 36761751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.
    Dang K; Castello G; Clarke SC; Li Y; Balasubramani A; Boudreau A; Davison L; Harris KE; Pham D; Sankaran P; Ugamraj HS; Deng R; Kwek S; Starzinski A; Iyer S; van Schooten W; Schellenberger U; Sun W; Trinklein ND; Buelow R; Buelow B; Fong L; Dalvi P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
    Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
    Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.
    Ellwanger K; Reusch U; Fucek I; Wingert S; Ross T; Müller T; Schniegler-Mattox U; Haneke T; Rajkovic E; Koch J; Treder M; Tesar M
    MAbs; 2019 Jul; 11(5):899-918. PubMed ID: 31172847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update.
    Alsajjan R; Mason WP
    Curr Oncol; 2023 Sep; 30(9):8501-8549. PubMed ID: 37754534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
    Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
    J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
    Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
    Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
    Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
    Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific T-cell Engagers in Metastatic Castration-Resistant Prostate Cancer.
    Hage Chehade C; Gebrael G; Agarwal N
    Cancer Discov; 2024 Jan; 14(1):20-22. PubMed ID: 38213299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms.
    Quinn DI; Shore ND; Egawa S; Gerritsen WR; Fizazi K
    Urol Oncol; 2015 May; 33(5):245-60. PubMed ID: 25575714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond.
    Lanka SM; Zorko NA; Antonarakis ES; Barata PC
    Curr Oncol; 2023 Apr; 30(4):4246-4256. PubMed ID: 37185436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate Cancer Immunotherapy-Finally in From the Cold?
    Runcie KD; Dallos MC
    Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pasotuxizumab, a BiTE
    Hummel HD; Kufer P; Grüllich C; Seggewiss-Bernhardt R; Deschler-Baier B; Chatterjee M; Goebeler ME; Miller K; de Santis M; Loidl W; Dittrich C; Buck A; Lapa C; Thurner A; Wittemer-Rump S; Koca G; Boix O; Döcke WD; Finnern R; Kusi H; Ajavon-Hartmann A; Stienen S; Sayehli CM; Polat B; Bargou RC
    Immunotherapy; 2021 Feb; 13(2):125-141. PubMed ID: 33172323
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.